Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17459607 | 0.83 | — | — | |
| SCHEMBL18307654 | 0.76 | — | — | |
| SCHEMBL16612115 | 0.75 | KMT2A (0.58) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL30429792 | 0.74 | HTR2C (0.44) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL4924522 | 0.74 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL420503 | 0.74 | CTSK (0.51) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL7350039 | 0.74 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL1508854 | 0.73 | HTR2C (0.52) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL28524807 | 0.73 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL19487131 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280780-B1 | ASYMMETRIC SYNTHESIS OF PIPERAZIC ACID AND DERIVATIVES THEREOF | VERTEX PHARMA (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6632942-B2 | 3S)-piperazic acid is derived from D-glutamic acid through an (R)-2,5-dihydroxyvalerate ester intermediate. After the hydroxy groups are converted to suitable leaving groups, such as mesylates, the ester is treated with a bis-protected | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-14 | — | — | US | disclosed |
| US-20030176691-A1 | Asymmetric synthesis of piperazic acid and derivatives thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-18 | — | — | US | disclosed |
| EP-1280780-A2 | ASYMMETRIC SYNTHESIS OF PIPERAZIC ACID AND DERIVATIVES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083458-A2 | ASYMMETRIC SYNTHESIS OF PIPERAZIC ACID AND DERIVATIVES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176691-A1 | Asymmetric synthesis of piperazic acid and derivatives thereof | CASP5, CASP2, CASP3 | MEN1 3989/4885KMT2A 1261/4885NPSR1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.